Amylyx Pharmaceuticals, Inc. (AMLX)
Source: FMP shares-float. FMP feed updated 2026-10-05 20:11:25 (timezone not supplied). The feed does not specify the effective date of this share count.
Shares outstanding measure the share count in the provider observation. Basic and diluted weighted averages below are EPS calculation inputs. Differences between these counts do not measure new issuance or buybacks.
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values. Q2 FY2026 (2026-06-30): 111.20M.
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values. Q2 FY2026 (2026-06-30): 111.20M.
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.
| Statement period | Period end | Weighted average basic shares | Weighted average diluted shares |
|---|---|---|---|
| Q2 FY2026 | 2026-06-30 | 111,196,883 | 111,196,883 |
| Q1 FY2026 | 2026-03-31 | 110,563,360 | 110,563,360 |
| Q4 FY2025 | 2025-12-31 | 94,565,567 | 94,565,567 |
| Q3 FY2025 | 2025-09-30 | 93,332,930 | 93,332,930 |
| Q2 FY2025 | 2025-06-30 | 89,138,568 | 89,138,568 |
| Q1 FY2025 | 2025-03-31 | 85,697,000 | 85,697,000 |
| Q4 FY2024 | 2024-12-31 | 68,593,499 | 68,593,499 |
| Q3 FY2024 | 2024-09-30 | 68,091,446 | 68,091,446 |
| Q2 FY2024 | 2024-06-30 | 68,024,929 | 68,024,929 |
| Q1 FY2024 | 2024-03-31 | 67,854,356 | 67,854,356 |
| Q4 FY2023 | 2023-12-31 | 67,414,669 | 69,196,421 |
| Q3 FY2023 | 2023-09-30 | 67,414,669 | 69,748,547 |
| Q2 FY2023 | 2023-06-30 | 67,233,617 | 70,132,040 |
| Q1 FY2023 | 2023-03-31 | 66,717,271 | 70,863,665 |
| Q4 FY2022 | 2022-12-31 | 65,416,712 | 65,416,712 |
| Q3 FY2022 | 2022-09-30 | 58,533,226 | 58,533,226 |
| Q2 FY2022 | 2022-06-30 | 58,136,559 | 58,275,903 |
| Q1 FY2022 | 2022-03-31 | 51,449,517 | 51,604,310 |
| Q4 FY2021 | 2021-12-31 | 55,216,013 | 55,216,013 |
| Q3 FY2021 | 2021-09-30 | 55,216,013 | 55,216,013 |
| Q2 FY2021 | 2021-06-30 | 45,951,470 | 45,951,470 |
| Q1 FY2021 | 2021-03-31 | 45,951,470 | 45,951,470 |
| Q4 FY2020 | 2020-12-31 | 45,951,470 | 45,951,470 |
FMP normalized EPS denominators, labeled by statement period end. These are weighted averages, not current shares outstanding. The provider's period duration may include year-to-date values.
| Statement period | Period end | Weighted average basic shares | Weighted average diluted shares |
|---|---|---|---|
| 2025 | 2025-12-31 | 94,565,567 | 94,565,567 |
| 2024 | 2024-12-31 | 68,142,000 | 68,142,000 |
| 2023 | 2023-12-31 | 67,234,465 | 69,991,340 |
| 2022 | 2022-12-31 | 66,512,011 | 66,512,011 |
| 2021 | 2021-12-31 | 57,864,186 | 57,864,186 |
| 2020 | 2020-12-31 | 56,466,013 | 56,466,013 |
| 2019 | 2019-12-31 | 56,466,013 | 56,466,013 |
